Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of around 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Boehringer Ingelheim Middle East and North Africa (MENA)
Boehringer Ingelheim MENA initiated its operations in in the Middle East and North Africa over 60 years ago in Egypt; today the company’s reach spreads to sales operation in 20 countries within MENA with a regional office in Dubai. The regional office in Dubai has then expanded its regional hub responsibility to manage the Middle East, Turkey and Africa (META) region.
Boehringer Ingelheim MENA is now one of the leading multinational pharmaceutical companies in the region with a team of over 800 employees.
Boehringer Ingelheim is dedicated to bringing innovative health care products in human pharmaceuticals and animal health to the Middle East and North Africa (MENA) region, through presence of scientific offices in KSA, Algeria, UAE, and Egypt. Boehringer Ingelheim operates in the rest of the MENA region through partners and third party distributors.
Boehringer Ingelheim’s businesses are divided into Human Pharma and Animal Health.
Human Pharma brings innovative products for different disease areas and is aimed at providing effective primary and specialty care across various indications, in order to improve the quality of life of patients in the Middle East and North Africa.
- Respiratory diseases
- Cardiovascular diseases
- Metabolic diseases - Diabetes
- Oncology
Animal Health provides innovative solutions in the Middle East and North Africa region, which improve health in:
- Livestock
- Equine
- Poultry.
Value through Innovation is the central concept of Boehringer Ingelheim’s corporate vision. Together with the corporate culture concept "Lead & Learn", this is the driver of the corporate culture.
At Boehringer Ingelheim MENA, providing the best possible care to patients is paramount. We thrive to infuse our corporate vision in to our business in the Middle East and North Africa by delivering effective disease awareness campaigns, supporting local healthcare communities and collaborating with governments and health authorities to provide a better quality of live to patients. We’ve manifested our commitment to “Care about making a positive difference to people’s quality of lives”.
Corporate Social Responsibility: Social responsibility is an important element of Boehringer Ingelheim MENA.
This includes region-wide involvement in social projects, such as the initiative “Making More Health”, creating disease awareness campaigns, educational programs and supporting local health authorities across MENA in providing better health awareness and care to patients.